Startseite>>Signaling Pathways>> Membrane Transporter/Ion Channel>> Sodium Channel>>Ralfinamide mesylate

Ralfinamide mesylate

Katalog-Nr.GC13283

Ralfinamidmesylat (FCE-26742A-Mesylat) ist ein oral verfÜgbarer Na+-Kanalblocker, abgeleitet von α-Aminoamid, mit schmerzunterdrÜckender Funktion.

Products are for research use only. Not for human use. We do not sell to patients.

Ralfinamide mesylate Chemische Struktur

Cas No.: 202825-45-4

Größe Preis Lagerbestand Menge
10mg
83,00 $
Ship Within 7 Days
50mg
334,00 $
Ship Within 7 Days

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Ralfinamide mesylate (FCE-26742A mesylate) is an orally available Na+ channel blocker derived from α-aminoamide, with function of suppressing pain[1][2].

Ralfinamide (30 mg/kg, 60 mg/kg; p.o.; twice daily; 42 days) treated with Ralfinamide (80 mg/kg; p.o.; twice daily; 7 days) preoperatively suppresses neuropathic pain[1].

References:
[1]. Zhang SH, et al. Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat. Pain. 2008 Oct 15;139(2):293-305.
[2]. Liang X, et al. Effects of ralfinamide in models of nerve injury and chemotherapy-induced neuropathic pain. Eur J Pharmacol. 2018 Mar 15;823:27-34.

Bewertungen

Review for Ralfinamide mesylate

Average Rating: 5 ★★★★★ (Based on Reviews and 3 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ralfinamide mesylate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.